Cellectis
CLLS
$2.56
Share price
1.59%
Change (1 day)
31.28%
Change (1 year)
Categories
Cellectis (CLLS) - Total debt
Total debt on the balance sheet as of September 2023 : $83.95 M
According to Cellectis's latest financial reports the company's total debt is $83.95 M. A company’s total debt is the sum of all current and non-current debts.
Cellectis - Total debt on balance sheet (from 2008 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $75.77 M | -24.88% |
| 2021-12-31 | $0.10 B | -5.44% |
| 2020-12-31 | $0.10 B | 124.08% |
| 2019-12-31 | $47.6 M | 3423.83% |
| 2018-12-31 | $1.35 M | 3873.53% |
| 2017-12-31 | $0.03 M | -98.07% |
| 2016-12-31 | $1.76 M | -18.98% |
| 2015-12-31 | $2.17 M | -51.53% |
| 2014-12-31 | $4.48 M | -20.17% |
| 2013-12-31 | $5.61 M | -1.29% |
| 2012-12-31 | $5.68 M | -91.77% |
| 2011-12-31 | $69.08 M | 2246.14% |
| 2010-12-31 | $2.94 M | 65.87% |
| 2009-12-31 | $1.77 M | -2.21% |
| 2008-12-31 | $1.81 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | $2.70 B | 3,119.65% | 🇺🇸 USA |
 uniQure QURE | $0.13 B | 64.87% | 🇳🇱 Netherlands |
 Novavax NVAX | $0.22 B | 172.88% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |